The PBMs say out-of-pocket insulin costs have fallen sharply since 2019. The Pharmaceutical Care Management Association, ...
In a move to address escalating insulin prices, the Federal Trade Commission (FTC) has initiated action against the three ...
FTC files lawsuit against top PBMs and GPOs for alleged anticompetitive practices in inflating insulin prices. Learn about the allegations and responses.
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated ...
The government’s antitrust watchdog on Friday sued three massive health conglomerates, accusing their drug middlemen of ...
The Federal Trade Commission is suing the titans of the pharmacy benefit ... “As the complaint explains, the PBMs have ...
The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a ...
The Federal Trade Commission has accused three major pharmacy benefit managers of inflating insulin prices, the agency said ...
Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...
The Federal Trade Commission has sued the three largest prescription drug benefit managers (PBMs) and their affiliated group purchasing organizations for engaging in anticompetitive and unfair rebatin ...
The Federal Trade Commission's administrative complaint follows an interim report from the agency regarding PBM practices.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback